How Has the GuillainBarre Syndrome Market Size Evolved in Recent Years?
The guillainbarre syndrome market has seen considerable growth due to a variety of factors.
• The market for guillain-barre syndrome has seen robust growth in recent years. It is projected to expand from $0.60 billion in 2024 to $0.64 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%.
The historical growth can be credited to an increased need for GBS therapies, a rise in viral infections, expansion of global vaccination drives, an improved grasp of autoimmune processes, and heightened awareness and diagnosis.
What are the Market Size and Expected Growth Rates for the GuillainBarre Syndrome Market?
The guillainbarre syndrome market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are that the market size for guillain-barre syndrome will experience significant growth over the next several years, projected to reach $0.79 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%.
Factors contributing to this growth during the forecast period include an increasing number of guillain-barre syndrome cases, the escalating impact of climate change, a greater use of immunotherapies and drugs, enhanced diagnostic capabilities, and a higher occurrence of multifocal motor neuropathy. In the forecast period, advancements such as improved diagnostic procedures, the creation of immunoglobulin therapies, enhanced plasmapheresis methods, the study of gene therapy, an emphasis on early intervention, the discovery of new prognosis biomarkers, and an increase in clinical trials for cutting-edge treatments are expected to be major trends.
Which Key Drivers Are Propelling The GuillainBarre Syndrome Market's Growth?
The surge in immunological diseases is set to fuel the expansion of the guillain-barre syndrome market in the future. These ailments, whether they make the immune system overly active, insufficiently active, or misguided, result in disorders like autoimmune diseases, allergies, and immunodeficiencies. There's an uptick in immunological diseases due to factors like environmental shifts, lifestyle choices, superior diagnostics, and genetic susceptibility. These diseases can induce guillain-barré syndrome, provoking an autoimmune response where the body's immunity system mistakenly assaults the peripheral nerves, causing inflammation and nerve damage. For instance, a report from July 2024 by the UN-run Joint United Nations Programme on HIV/AIDS, a Switzerland-based government organization, announced that by 2022 the number of people suffering from HIV worldwide was around 39.5 million, with 1.3 million new cases and 630,000 AIDS-related deaths that year. By 2023, the number of HIV carriers globally increased to roughly 39.9 million. Hence, the accelerating risk of immunological diseases is propelling the guillain-barre syndrome market.
What Are The Key Segments Within The Global GuillainBarre Syndrome Market?
The guillain-barre syndrome market covered in this report is segmented –
1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By Route Of Administration: Parenteral, Oral
4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP
3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis
Pre-Book The GuillainBarre Syndrome Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The GuillainBarre Syndrome Market?
Top firms in the guillain-barre syndrome market are focusing on the development of innovative drugs like monoclonal antibodies to boost treatment effectiveness, fulfill unmet medical needs, and broaden their market reach. These monoclonal antibodies are proteins engineered in a lab to target specific antigens, aiding in the regulation of immune responses and enhancing therapeutic results. For instance, Annexon Inc., an American biopharmaceutical firm, was granted orphan drug status by the European Medicines Agency (EMA) for ANX005, a treatment for guillain-barre syndrome, in October 2023. This monoclonal antibody focuses on C1q and showed early signs of improving muscle strength and decreasing the necessity for ventilation relative to IVIg, signifying a notable progress in therapy.
Who Are the Key Players In The GuillainBarre Syndrome Market?
Major companies operating in the guillain-barre syndrome market are:
• Pfizer Inc.
• Roche AG
• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• GSK plc
• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• Baxter International Inc.
• Biogen Inc.
• Horizon Therapeutics
• Octapharma AG
• Kedrion S.p.A.
• Annexon Inc.
• Immunovant Inc.
• CSL Behring LLC
• Hansa Biopharma AB
• NeuLine Health Inc.
• Ridge Diagnostics Inc.
• Deymed Diagnostic LLC
• VYVGART Hytrulo.
What Are The Regional Insights Into The GuillainBarre Syndrome Market?
North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
